20/20 Biolabs Stock Price, News & Analysis
Company Description
20/20 BioLabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for early detection and prevention of cancers and chronic diseases. The company trades on Nasdaq under the symbol AIDX and operates as a commercial-stage diagnostics company centered on the OneTest brand. Its model combines blood-based laboratory testing, machine-learning analytics, and software-enabled reporting to support disease-risk assessment and biomarker tracking.
The company's primary commercial product family is OneTest for Cancer, a multi-cancer early detection, or MCED, blood test. The test is based on a patented protein tumor marker methodology and machine-learning-derived analysis. 20/20 BioLabs positions this approach as distinct from MCED methods that rely solely on circulating tumor DNA, with company materials emphasizing protein biomarkers as a core element of its early-stage cancer screening methodology.
OneTest for Longevity is the company's chronic disease risk assessment and management product family. The test measures inflammatory biomarkers and uses AI-enabled analysis to calculate and display risk information for chronic diseases such as diabetes, dementia, and cardiovascular disease. The product also provides evidence-based dietary recommendations tied to biomarker levels and related disease-risk patterns. Company materials state that the Longevity solution uses IBM watsonx.ai as an AI application development environment, with IBM serving as an information technology provider rather than a medical provider.
20/20 BioLabs processes its tests in a College of American Pathologists accredited and Clinical Laboratory Improvement Amendments licensed laboratory in Gaithersburg, Maryland. The company's materials describe home-accessible sample collection using upper-arm capillary collection devices, as well as distribution through clinical and practitioner channels. Its commercial customer and end-market references include functional and integrative medicine practitioners, public-sector cancer screening programs, occupational health markets, firefighters, veterans, self-insured employers, and direct-to-consumer sales efforts.
The company also operates CLIAx, described as a shared CLIA laboratory model for overseas diagnostics start-ups seeking to launch novel laboratory tests in the United States without establishing their own independent laboratory. Its legacy business includes BioCheck, a field test kit used for screening suspicious powders for bioterror agents.
20/20 BioLabs is an emerging growth company and smaller reporting company in its SEC registration materials. Its public-company record includes registration statements, material-event reports, financial-results disclosures, and capital-structure filings associated with its Nasdaq listing and financing arrangements.
Stock Performance
20/20 Biolabs (AIDX) stock last traded at $0.9500, down 12.63% from the previous close. Over the past 12 months, the stock has lost 96.5%. At a market capitalization of $10.9M, AIDX is classified as a micro-cap stock with approximately 10.6M shares outstanding.
AIDX Rankings
Latest News
20/20 Biolabs has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include earnings. View all AIDX news →
SEC Filings
20/20 Biolabs has filed 5 recent SEC filings, including 2 Form 424B3, 1 Form PRE 14A, 1 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on June 1, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AIDX SEC filings →
Financial Highlights
20/20 Biolabs generated $2.0M in revenue over the trailing twelve months, retaining a 29.6% gross margin, operating income reached -$3.3M (-162.9% operating margin), and net income was -$3.7M, reflecting a -182.8% net profit margin. Diluted earnings per share stood at $-0.76. The company generated -$1.9M in operating cash flow. With a current ratio of 0.60, short-term liquidity bears monitoring.
Upcoming Events
Medicare MCED coverage begins
Medicare coverage begins
20/20 Biolabs has 2 upcoming scheduled events. The next event, "Medicare MCED coverage begins", is scheduled for January 1, 2028 (in 575 days). Investors can track these dates to stay informed about potential catalysts that may affect the AIDX stock price.
Short Interest History
Short interest in 20/20 Biolabs (AIDX) currently stands at 33.1 thousand shares, up 74.8% from the previous reporting period, representing 0.3% of the float. Over the past 12 months, short interest has increased by 75.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for 20/20 Biolabs (AIDX) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
AIDX Company Profile & Sector Positioning
20/20 Biolabs (AIDX) operates in the Medical Devices industry within the broader Services-testing Laboratories sector and is listed on the NASDAQ.